Correlation Engine 2.0
Clear Search sequence regions


  • celecoxib (4)
  • cGMP (1)
  • COX2 (1)
  • cox2 inhibitor (2)
  • cyclic (2)
  • humans (1)
  • PDE5 (7)
  • pde5 inhibitors (3)
  • phosphodiesterases (2)
  • pyrazoles (2)
  • Sizes of these terms reflect their relevance to your search.

    Celecoxib, is a selective cyclooxygenase-2 (COX2) inhibitor with a 1,5-diaryl pyrazole scaffold. Celecoxib has a better safety profile compared to other COX2 inhibitors having side effects of systemic hypertension and thromboembolic complications. This may be partly attributed to an off-target activity involving phosphodiesterase 5 (PDE5) inhibition and the potentiation of NO/cGMP signalling allowing coronary vasodilation and aortic relaxation. Inspired by the structure of celecoxib, we synthesized a chemically diverse series of compounds containing a 1,3,5-trisubstituted pyrazoline scaffold to improve PDE5 inhibitory potency, while eliminating COX2 inhibitory activity. SAR studies for PDE5 inhibition revealed an essential role for a carboxylic acid functionality at the 1-phenyl and the importance of the non-planar pyrazoline core over the planar pyrazole with the 5-phenyl moiety tolerating a range of substituents. These modifications led to new PDE5 inhibitors with approximately 20-fold improved potency to inhibit PDE5 and no COX-2 inhibitory activity compared with celecoxib. PDE isozyme profiling of compound 11 revealed a favorable selectivity profile. These results suggest that trisubstituted pyrazolines provide a promising scaffold for further chemical optimization to identify novel PDE5 inhibitors with potential for less side effects compared with available PDE5 inhibitors used for the treatment of penile erectile dysfunction and pulmonary hypertension. Copyright © 2020 Elsevier Inc. All rights reserved.

    Citation

    Mohammad Abdel-Halim, Heather Tinsley, Adam B Keeton, Mohammed Weam, Noha H Atta, Mennatallah A Hammam, Amr Hefnawy, Rolf W Hartmann, Matthias Engel, Gary A Piazza, Ashraf H Abadi. Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors. Bioorganic chemistry. 2020 Nov;104:104322

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33142429

    View Full Text